Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C

Anticancer Research

Volumn 26, Issue 1 B, 2006, Pages 599-603

  Brivio, Fernando ^a,b   Fumagalli, Luca ^a   Lissoni, Paolo ^b   Nardone, Armando ^a   Nespoli, Luca ^a   Fattori, Luca ^a   Denova, Marianna ^a   Chiarelli, Marco ^a   Nespoli, Angelo ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

Colorectal cancer; Immunodeficiency; Immunotherapy; Interleukin 2

Indexed keywords

ANTIHISTAMINIC AGENT; CEFOXITIN; FLUOROURACIL; FOLIC ACID DERIVATIVE; RECOMBINANT INTERLEUKIN 2;

ADULT; ADVANCED CANCER; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER IMMUNOLOGY; CANCER STAGING; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNE DEFICIENCY; IMMUNOPROPHYLAXIS; MALE; MINIMAL RESIDUAL DISEASE; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PRURIGO; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM CANCER; SHORT COURSE THERAPY; SURGICAL INJURY;

ADULT; AGED; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE;

EID: 32144448181     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kim U, Papatestas A and Aufses AH: Prognostic significance of peripheral lymphocyte counts and carcynoembryogenic antigens in colorectal carcinoma. J Surg Onc 8: 257-262, 1976.
2. Yamaguchi K, Maeda S and Kitamura K: Prognostic factors in colorectal carcinoma: significance of peripheral T lymphocytes. Int Surg 74: 232-239, 1989.
3. Eibler FR, Nizze JA and Morton DL: Sequential evaluation of general immune competence in cancer patients: correlation with clinical course. Cancer 35: 660-665, 1975.
4. Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M and Miyazaki M: Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg 20: 445-451, 2003.
5. Shafir M, Bekesi JG, Papatestas A, Slater G and Aufses AH: Preoperative and post-operative immunological evaluation of patients with colorectal cancer. Cancer 46: 700-705, 1980.
6. Maltoni M, Pirovano M, Nanni O, Marinari M, Indelli M, Gramazio A, Terzoli E, Luzzani M, De Marinis F, Caraceni A and Labianca R: Biological indices predictive of survival in 519 Italian terminally ill cancer patients. J Pain Symptom Manage 13: 1-9, 1997.
7. Lahm H, Shindel M, Frikart L, Cerottini JP, Yilmaz A, Givel JC and Fischer JR: Selective suppression of cytokine secretion in whole blood cell cultures of patients with colorectal cancer. Br J Cancer 78(8): 1018-1023, 1998.
8. Ikeguchi M, Saito H, Katano K, Tsujitani S, Maeta M and Kaibara N: Correlation between the lymphocytic infiltration of tumours and the proliferative activity of cancer cells from surgically treated oesophageal carcinoma. Oncology 54: 311-317, 1997.
9. Jass JR, Love SB and Northover JMA: A new prognostic classification of rectal cancer. The Lancet 6: 1303-1306, 1987.
10. Jass JR: Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 39: 585-589, 1986.
11. Pastrnak A and Jamsa P: Local eosinophilia in stroma of tumor related to prognosis. Neoplasma 31(3): 323-326, 1984.
12. Pretlow TP Keith EF, Cryar AK, Bartolucci AA, Pitts AM, Pretlow TG, Kimball PM and Boohaker EA: Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res 43: 2997-3000, 1983.
13. Shenkin A, Fraser WD and Seris J: The serum interleukin-6 responses to elective surgery. Lymphokine Res 8: 123-127, 1989.
14. Ayala A, Wang P, Ba ZF, Perrin MM, Ertel W and Chaudry IH: Differential alterations in plasma IL-6 and TNF levels after trauma and haemorrhage. Am J Physiol 260: 167-171, 1991.
15. Zhou D, Munster AM and Winchurch RA: Inhibitory effects of interleukin-6 on immunity. Arch Surg 127: 65-69, 1992.
16. Akiyoshi T, Koba F, Arinaga S, Miyazaki S, Wada T and Tsuji H: Impaired production of IL-2 after surgery. Clin Exp Immunol 59: 45-49, 1985.
17. Eggermont AMM, Steller EP and Sugarbaker PH: Laparotomy enhances intraperitoneal tumour growth and abrogates the antitumor effects of Interleukin-2 and lymphokine-activated killer cells. Surgery 102: 71-78, 1987.
18. Brivio F, Lissoni P, Mancini D, Tisi E, Tancini G, Barni S and Nociti V: Effect of antitumor surgery on soluble Interleukin-2 receptor serum levels. Am J Surg 161: 466-469, 1991.
19. Rubin LA, Jay G and Nelson DL: The released interleukin-2 receptor binds interleukin-2 efficiently. J Immunol 137: 3841-3844, 1986.
20. Koch M, Weitz J and Kienle P: Comparison analysis of tumour cell dissemination in mesenteric, central, and peripheral venous blood in patients with colorectal cancer. Arch Surg 136: 85-89, 2001.
21. Brivio F, Fumagalli L, Brivio O, Castoldi M, Franciosi C, Rescaldani R and Uggeri F: Immune response to surgical trauma and its relationship with prognosis in patients submitted to surgery for colo-rectal cancer. Chirurgia 11: 379-381, 1998.
22. Grimm EA, Mazumder A, Zhang HZ and Rosenberg SA: Lymphokine-activated killer cell phenomenon. J Exp Med 155: 1823-1841, 1982.
23. Brivio F, Lissoni P, Tisi E, Erba L, Barni S, Tancini G, Rescaldani R, Alderi G and Nociti V: Effects of a pre-operative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients. Oncology 49(3): 215-218, 1992.
24. Brivio F, Lissoni P, Barni S, Tancini G, Ardizzoia A, Erba L, Alderi G and Nociti V: Effect of a pre-operative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: a phase II study. Eur J Surg 159: 43-47, 1993.
25. Deehan DJ, Heys SD, Ashby J and Eremin O: Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease. Eur J Oncol 21: 16-22, 1995.
26. Nichols PH, Ramsden CW, Ward U, Sedman PC and Primrose JN: Perioperative immunotherapy with recombinant interleukin-2 in patients undergoing surgery for colorectal cancer. Cancer Res 52(20): 5765-5769, 1992.
27. Böhm M, Ittenson A, Schierbaum KF, Röhl W, Ansorge S and Allhoff EP: Pretreatment with Interleukin-2 modulates peri-operative immuno-dysfunction in patients with renal cell carcinoma. Eur Urol 41: 458-468, 2002.
28. Romano F, Cesana G, Berselli M, Piacentini MG, Caprotti R, Bovo G and Uggeri F: Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients. J Surg Oncol 88: 240-247, 2004.
29. Colacchio TA, Yeager MP and Hildebrandt LW: Perioperative immunomodulation in cancer surgery. Am J Surg 167: 174-179, 1994.
30. Brivio F, Lissoni P, Fumagalli L, Girlando M, Marsili MT, Nespoli A and Uggeri F: Pre-operative IL-2 immunoprophylaxis of cancer recurrence: long term clinical results of a phase II study in radically operable colorectal cancer. Oncol Rep 6: 1205-1207, 1999.
31. Atzpodien J and Kirchner H: Cancer, cytokines and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasm. Woechenschr 68: 1-11, 1990.
32. Bocci V, Pessina GP, Nicoletti C and Paulesu L: The lymphatic route. Distribution of recombinant human interleukin-2 in rabbit plasma and lymph. J Biol Regl Homeost Agents 4: 25-29, 1990.
33. Brivio F, Lissoni P, Brivio O, Marsili MT, Alderi G, Lavorato F, Fumagalli L and Uggeri F: Timing and schedule of perioperative immunotherapy with interleukin-2 in oncological surgery. J Emerg Surg Intensive Care 19(2): 59-62, 1996.
34. Brivio F, Lissoni P, Alderi G, Barni S, Lavorato F and Fumagalli L: Pre-operative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients. Oncology 53: 263-268, 1996.
35. Fumagalli L, Vinke J, Hoff W, Ypma E, Brivio F and Nespoli A: Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 26(5): 394-402, 2003.
36. Brivio F, Lissoni P, Perego M, Lissoni A and Fumagalli L: Abrogation of surgery-induced IL-6 hypersecretion by presurgical immunotherapy with IL-2 and its importance in the prevention of post-operative complications. J Biol Regul Homost Agents 10: 370-374, 2001.
37. Brivio F, Gilardi R, Bucocev R, Ferrante R, Rescaldani R, Vigorè R and Fumagalli L: Surgery induced decline in circulating dendritic cells in operable cancer patients. A possible explanation of post-operative immunosuppression. Hepatogastroenterol 47: 1337-1339, 2000.
38. Brivio F, Lissoni P, Gilardi R, Ferrante R, Vigore' R, Curzi L, Uggeri F and Nespoli A: Abrogation of surgery induced decline in circulatimg dendritic cells by subcutaneous pre-operative administration of IL-2 in operable cancer patients. J Biol Regul Homost Agents 9: 200-203, 2000.
39. Brivio F, Lissoni P, Rovelli F, Nespoli A and Uggeri F: Effects of IL-2 pre-operative immunotherapy on surgery- induced changes in angiogenetic regulation and its prevention of VEGF increase and IL-12 decline. Hepatogastroenterol 49: 385-387, 2002.
40. Bovo G, Brivio F, Brenna A, Fumagalli L, Perego P, Brivio O, Uggeri F, Lavorato F and Bratina G: Pre-operative Interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma. Pathologica 87: 135-138, 1995.